CARM1 and prostate carcinoma: The anti-proliferative effect of EZM2302 treatment was assessed in a panel of solid tumor cell lines representing indications in which CARM1 has been hypothesized in the literature to play an oncogenic role, including breast, colorectal, and prostate carcinoma.